<DOC>
	<DOCNO>NCT00017563</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give chemotherapy surgery may shrink tumor remove surgery . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy follow surgery treating patient localized prostate cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Surgery Treating Patients With Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine 5-year freedom prostate-specific antigen ( PSA ) recurrence patient treat regimen . - Define maximum tolerate dose neoadjuvant docetaxel mitoxantrone follow prostatectomy patient high-risk localized prostate cancer . ( Phase I complete 2/15/02 ) - Determine toxicity regimen patient . - Determine PSA response rate pathologic response rate patient treat regimen . - Determine clinical response patient treat regimen . - Determine overall survival patient treat regimen . - Determine surgical margin status time prostatectomy patient treat regimen . OUTLINE : This dose-escalation study mitoxantrone . ( Phase I complete 2/15/02 ) Patients receive neoadjuvant docetaxel mitoxantrone weekly week 1-3 . Treatment repeat week total 4 course . Patients receive escalate dos mitoxantrone maximum tolerate dose determine . ( Phase I complete 2/15/02 ) Patients undergo prostatectomy 2-4 week completion neoadjuvant chemotherapy . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Highrisk , define 1 following : Stage T2b ( palpable bilateral involvement ) surgically resectable T3 PSA 15 ng/mL great Gleason grade great 4+3 ( 4+3 , 4+4 , 5+any , 3+4 ) At least 50 % chance prostate cancer recurrence within 5 year Planned prostatectomy primary therapy No evidence bone metastases bone scan No evidence lymph node great 2 cm pelvic compute tomography ( CT ) scan ( scan require PSA great 40 ng/mL ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy : At least 10 year Hematopoietic : White Blood Cell ( WBC ) least 3,000/mm^3 Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Conjugated bilirubin great upper limit normal ( ULN ) Alkaline phosphatase great 4 time ULN Alanine transaminase ( ALT ) great 2 time ULN ( 1.5 time ULN alkaline phosphatase great 2.5 time ULN ) Renal : Not specify Cardiovascular : Ejection fraction great 50 % Multiple Gated Acquisition ( MUGA ) scan Other : No malignancy within past 5 year except nonmelanoma skin cancer No significant active medical illness would preclude study therapy No peripheral neuropathy grade 2 great No hypersensitivity drug formulate polysorbate80 No significant contraindication corticosteroid PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy No concurrent cytotoxic chemotherapy Endocrine therapy : No prior concurrent conventional hormonal therapy Radiotherapy : No prior concurrent radiotherapy ( external beam brachytherapy ) Surgery : See Disease Characteristics Other : No prior concurrent cryotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>